Michael Johnson, MD

Specializes In
  • Urology
Languages Spoken
  • English


Sees Patients For

Robotic surgery, prostate cancer, kidney cancer, vasectomy

Hospital Affiliations

  • Barnes-Jewish St. Peters Hospital
  • Barnes-Jewish West County Hospital



Board Certifications

  • Urology

Academic Title(s)

Interim Chief, Urology
Professor, Surgery

Research Interests

Digital medical technology, clinical trials, practice optimization

Publications & Research

View research profile »


Fellowship: Urologic Oncology

2016 Johns Hopkins University School of Medicine, Baltimore, MD

Residency: Urologic Surgery

2014 Washington University School of Medicine, St. Louis, MO

Medical Degree

2009 University of Washington School of Medicine, Seattle, WA

Financial Disclosures
  • Janssen Pharma
    • Speaker Fees: $10,000 - $19,999
    • Reporting Date: 05/01/2024
  • Merck
    • Speaker Fees: $10,000 - $19,999
    • Reporting Date: 05/01/2024

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.